慢性骨髓增殖性疾病患者中JAK2V617F突变与BCR-ABL基因重排的同时发生。 - Suppr

Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.

作者信息

Kim Yeo-Kyeoung, Shin Myung-Geun, Kim Hye-Ran, Yang Deok-Hwan, Cho Sang-Hee, Lee Je-Jung, Chung Ik-Joo, Ryang Dong-Wook, Kim Hyeoung-Joon

出版信息

Leuk Res. 2008 Jun;32(6):993-5. doi: 10.1016/j.leukres.2007.10.018. Epub 2007 Dec 4.

DOI:10.1016/j.leukres.2007.10.018

PMID:18055011

Abstract

摘要

相似文献

Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.

Leuk Res. 2008 Jun;32(6):993-5. doi: 10.1016/j.leukres.2007.10.018. Epub 2007 Dec 4.

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

Leukemia. 2008 May;22(5):1059-62. doi: 10.1038/sj.leu.2404993. Epub 2007 Nov 1.

Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.

Tokai J Exp Clin Med. 2007 Dec 20;32(4):131-5.

[Molecular bases of leukemia, MPD and MDS].

Rinsho Ketsueki. 2009 Mar;50(3):174-81.

A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.

Cancer Genet Cytogenet. 2010 May;199(1):1-8. doi: 10.1016/j.cancergencyto.2010.01.002.

JAK2-V617F and BCR-ABL--double jeopardy?

Leuk Res. 2008 Oct;32(10):1489-90. doi: 10.1016/j.leukres.2008.03.011. Epub 2008 Apr 24.

The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.

J Med Life. 2013 Mar 15;6(1):34-7. Epub 2013 Mar 25.

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

Trends Mol Med. 2005 Dec;11(12):546-54. doi: 10.1016/j.molmed.2005.10.003. Epub 2005 Nov 3.

Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.

Leukemia. 2007 Sep;21(9):2051; author reply 2052. doi: 10.1038/sj.leu.2404825. Epub 2007 Jun 28.

Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.

Leuk Res. 2009 Aug;33(8):1144-6. doi: 10.1016/j.leukres.2009.03.011. Epub 2009 Apr 25.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.

Int J Hematol. 2023 Mar;117(3):456-462. doi: 10.1007/s12185-022-03463-0. Epub 2022 Oct 1.

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):331-4. doi: 10.1007/s12288-014-0385-1. Epub 2014 Apr 11.

Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Ann Lab Med. 2013 May;33(3):229-32. doi: 10.3343/alm.2013.33.3.229. Epub 2013 Apr 17.

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Int J Hematol. 2013 Jun;97(6):804-7. doi: 10.1007/s12185-013-1326-8. Epub 2013 Apr 24.

JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Int J Hematol. 2013 Mar;97(3):435-7. doi: 10.1007/s12185-013-1287-y. Epub 2013 Feb 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献